© 1996 American Heart Association, Inc.
Articles |
Plasminogen Activator Inhibitor–1, Tissue-Type Plasminogen Activator, and Fibrinogen
Effect of Dieting With or Without Exercise in Overweight Postmenopausal Women
From the Center for Clinical and Basic Research (O.L.S., C.H., C.C.), Ballerup; the Department of Clinical Chemistry (J.D.N.), Gentofte Hospital, Gentofte; and the Department of Clinical Chemistry (K.W.), Kolding Hospital, Kolding, Denmark.
Correspondence to Ole Lander Svendsen, MD, Center for Clinical and Basic Research, Ballerup Byvej 222, DK-2750 Ballerup, Denmark, or Kaj Winther, MD, Department of Clinical Chemistry, Kolding Hospital, DK-6000 Kolding, Denmark.
 |
Abstract |
|---|
 Top Abstract IntroductionMethods Results Discussion References |
|---|
Abstract This study assessed the short- and long-term effects of an energy-restrictive diet with or without exercise on plasminogen activator inhibitor–1 antigen (PAI-1 Ag) and PAI-1 activity, tissue-type plasminogen activator antigen (TPA Ag), and fibrinogen serum levels. Healthy, overweight postmenopausal women (age, 53.8±2.5 years; body mass index, 25 to 42 kg/m2; n=121) were randomly assigned to one of three groups: control, 4200-kJ/d diet, or 4200-kJ/d diet with combined aerobic and anaerobic exercise. PAI-1 activity and PAI-1 Ag, TPA Ag, and fibrinogen levels were measured at baseline, after a 12-week intervention, and after a further 6-month follow-up. PAI-1 Ag and activity and TPA Ag were positively correlated with serum triglyceride levels, the abdominal-to–total-body fat ratio (as assessed by total-body dual-energy x-ray absorptiometry), fasting blood glucose, and systolic BP and negatively with HDL cholesterol and sex hormone–binding globulin. The diet led to profound decreases and normalization of PAI-1 activity (
50%), PAI-1 Ag (30%), and TPA Ag (29%), but exercise
conferred no additional effect. Fibrinogen did not change. At
follow-up there were no longer any significant changes
(P>.05). In conclusion, PAI-1 Ag and activity as well as
TPA Ag seem to be part of the metabolic syndrome X. The
diet made the blood less thrombogenic in the short term with no effect
of the added exercise.
Key Words: diet • plasminogen activator inhibitor–1 • fibrinogen • exercise • postmenopausal
|
Introduction |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
In the industrialized world, CVD is currently the leading cause of death and disability in women.1 Several recently established risk factors for CVD include high levels of PAI-1 activity, TPA Ag, and fibrinogen.2 3 4 5 High levels of PAI-1 activity have been suggested as being part of syndrome X and as the link between insulin resistance and CVD.3 6 In women, an android sex hormone status may also take part in this syndrome.7 8 9
Weight loss by dieting seems to lower PAI-1 activity and TPA Ag, whereas the reported effects on fibrinogen conflict.10 11 The effect of adding exercise to an energy-restrictive diet has not been reported. We have shown that 12 weeks of an energy-restrictive diet in overweight postmenopausal women resulted in a 10-kg (13%) weight loss and to profound improvements (20% to 30%) in several cardiovascular risk factors without any additional effect from exercise.12 At a 6-month follow-up the weight loss was about 8 kg and there were still significant improvements in some of the risk factors for CVD.13 The present study, which presents an extension of those two reports,12 13 assessed the short- and long-term effects of an energy-restrictive diet with or without exercise on PAI-1, TPA, and fibrinogen in overweight postmenopausal women. Associations of PAI-1, TPA, and fibrinogen with sex hormones and cardiovascular risk factors are also discussed.
|
Methods |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
Subjects and Study Design
Healthy, overweight postmenopausal women (age, 53.8±2.5 years; body mass index, 25 to 42 kg/m2; n=121) were initially randomized to one of three groups for 12 weeks of intervention: a diet-only group (n=51), a diet-plus-exercise group (n=49), and a control group (n=21).12 Briefly, the diet consisted of an obligatory basis of the formula diet NUPO (Oluf Mørk Biochemie A/S), which supplied 65 g protein and 1.6 MJ daily (within which international recommendations are met) and an additional 2.6 MJ daily from food freely chosen according to a "counter diet system."14 The exercise consisted of supervised combined aerobic exercise (
70% of VO2 max) and
resistance weight training (65% of maximum weight-lifting
capacity) for 1 hour, increasing to 1
hours,
three times per
week. There were no statistically significant differences between groups in baseline values; 118 women completed the 12-week study, the results of which are available.12 Briefly, the maximum oxygen uptake (33% versus 12%) and the loss of fat tissue mass (-9.6 versus -7.8 kg) were significantly increased, whereas the lean tissue mass was preserved (0.0 versus -1.2 kg) in the diet-plus-exercise group compared with the diet-only group. At the end of the 12-week intervention, the women were encouraged to continue to exercise and to use the counter diet system to avoid weight gain. After 6 months on their own, the women (n=110) were reexamined.13 Baseline correlations and changes in parameters other than PAI-1, TPA, and fibrinogen are available.9 12 13
The study was performed in accordance with the Declaration of Helsinki II and with the approval of the ethics committee of Copenhagen County.
Body Composition
Total as well as abdominal (from the first
to the fourth lumbar
intervertebral disk) body composition was measured by using a
total-body dual-energy x-ray absorptiometry scanner (DPX,
Lunar Radiation Corp, software version
3.2).15 16 17
Total-body bone mineral density, fat tissue mass, and lean tissue
mass were measured. The fat tissue mass is not solely adipose tissue,
but the sum of the fatty elements of all the soft tissues. Similarly,
the lean tissue mass is not an anatomic entity but represents
the sum of all chemically fat-free soft tissue elements.
Biochemistry
Blood samples were taken in the morning after an
overnight fast
of at least 12 hours. If the time of blood sampling between samples for
individual subjects differed by more than 1 hour, the samples for PAI-1
and TPA were not analyzed (due to a well-known individual
circadian variation). The samples were stored at -80°C until
analyzed.
Blood (4.5 mL) was collected in tubes containing 3.13% citrate (0.5 mL) and centrifuged at 2000g for 10 minutes at room temperature. PAI-1 activity was then determined spectrophotometrically by using the reagent spectrolyse/pL (No. 101201, Biopool AB) (intra-assay variation, 4.4% to 9.3%; reference range, 5.5±5 IU/mL). The mean of duplicate measurements was used. PAI-1 Ag and TPA Ag levels were measured by using enzyme-linked immunosorbent assays: COALIZA PAI-1 (intra-assay, 4% to 6%; interassay variation, 6% to 8%; reference range, 40.0±29 ng/mL) and COALIZA t-PA, which determines free TPA Ag as well as TPA Ag bound by PAI-1 (intra-assay variation, 7%; interassay variation, 4% to 7%; reference range, 1 to 12 ng/mL) (both from Chromogenix AB). Fibrinogen was measured photometrically by using a Cobas Mira Plus after proteolytic cleavage with batroxobin (Fibrinogen Kinetic, Boehringer Mannheim, catalogue No. 524484; reference range, 2.0 to 4.0 g/L).
HDL-C was isolated by using a phosphotungstic acid–MgCl2 precipitation technique.18 Serum total cholesterol, triglyceride, and HDL-C levels were determined enzymatically by Chem1 (CHOD-PAP method, Technicon Instruments). VLDL and LDL cholesterol levels were calculated according to the formula of Friedewald et al.19
Total serum testosterone and SHBG, which primarily binds testosterone and is believed to be an indicator of androgen status,20 were measured in unextracted serum by a radioimmunoassay and an immunoradiometric assay, respectively (Coat-a-count, Diagnostic Products Corp). Estradiol-17-ß (anti-17-beta-oestradiol-6-BSA-serum; BioMakor) and androstenedione (specific antibody; Wien Laboratories Inc) were measured by using a radioimmunoassay. The mean of duplicate measurements was used for all hormone determinations.
BP was measured once after 10 minutes of supine rest by using a digital BP meter (A&D) read to the nearest 5 or 10 mm Hg.
Calculations and Statistical Analysis
The
abdominal-to–total-body fat tissue mass and
waist-to-hip circumference ratios were calculated as indicators
of fat distribution.
The Statistical Analysis System (SAS Institute Inc) was used for all analyses. Because a test of normality (proc UNIVARIATE) revealed that PAI-1 activity and PAI-1 Ag, TPA Ag, and fibrinogen levels were not normally distributed (P<.05), the nonparametric medians and 95% confidence intervals are reported. Differences in changes between groups were compared by using the nonparametric Kruskal-Wallis test (proc NPAR1WAY). The nonparametric Spearman rank correlation coefficients were also computed. Significance was established as P>.05.
|
Results |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
As shown in Table 1
, PAI-1 activity and PAI-1 Ag
and TPA Ag levels were positively correlated with abdominal fat
distribution, systolic BP, fasting blood glucose, and serum
triglycerides and negatively correlated with HDL-C and
SHBG. Fibrinogen, on the other hand, correlated positively with
diastolic BP, fat tissue mass, and total testosterone
concentration.
|
The baseline levels of PAI-1 activity and PAI-1 Ag (Table 2)
were high compared with the reference ranges of the
assays, whereas the levels of TPA and fibrinogen were more within the
reference ranges.
|
After the 12 weeks of intervention, PAI-1 Ag (by 30%), TPA Ag (by
29%), and PAI-1 activity (by 46%) were significantly decreased
in both the diet-only and diet-plus-exercise groups
compared with the control group (Table 2
and the
Figure).
|
During the follow-up period, PAI-1 Ag, TPA Ag, and PAI-1 activity
were significantly increased in both intervention groups compared with
the control group (Table 2). Therefore, there were no
significant
changes in PAI-1 Ag, TPA Ag, and PAI-1 activity from baseline to the
end of the follow-up period in either the diet-only or
diet-plus-exercise group compared with the control group (Table
2 and the Figure).
There was no change in fibrinogen level after the 12 weeks of intervention. However, fibrinogen was significantly decreased from baseline to the end of the follow-up period in the diet-only and diet-plus-exercise groups compared with the control group due to a nonsignificant increase during the follow-up period in the control group.
There were no significant differences between changes in the diet-only and diet-plus-exercise groups in PAI-1 activity or PAI-1 Ag, TPA Ag, or fibrinogen levels after the intervention or at follow-up (P>.05).
|
Discussion |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
Our results agree with the existence of a metabolic syndrome X within healthy, nondiabetic, normotensive, overweight, postmenopausal women. This syndrome seems to include not only an abdominal fat distribution, low HDL-C levels, hypertriglyceridemia, high BP, and high blood glucose but also a high PAI-1 activity as well as an android sex hormone status (as indicated by the negative association with SHBG). This is in accordance with previous reports.3 7 21 22 23 24 We and others have found that fibrinogen is associated with obesity.2 11 25 26 On the other hand, in the present overweight postmenopausal women, fibrinogen was not associated with fat distribution, which is in contrast to the findings of others.25 27
In our randomized controlled study of healthy overweight postmenopausal
women, PAI-1 Ag and PAI-1 activity were increased at baseline. The diet
led to a profound decrease in PAI-1 Ag but also to a decrease in TPA
Ag. There was an 50% decrease in the PAI-1 activity, which dropped
into the reference range of the assay. On the other hand, there was no
effect on fibrinogen levels, which were within the normal range
from baseline. Besides our study, only one randomized controlled study
of the effect of weight loss by dieting on PAI-1 Ag, TPA Ag, and
fibrinogen levels is available.11 Six months of dieting
with a weight loss of 7 to 9 kg led to a 31% decrease in PAI-1 Ag and
a 24% decrease in TPA Ag but no significant changes in fibrinogen. As
reviewed by Folsom et al,11 this is in accordance with
uncontrolled studies of PAI-1 activity and PAI-1 Ag and TPA Ag levels.
However, the effect of weight loss by dieting on fibrinogen in
uncontrolled studies differs between the
studies.10 11 The
importance of control groups in intervention studies of fibrinolytic
factors and fibrinogen is stressed by the spontaneous variation
with season in these parameters.28 29 In our
study PAI-1 Ag and TPA Ag tended to decrease and fibrinogen to increase
in the control group during the follow-up period. This may result
from a seasonal variation, since the intervention was during the summer
and the follow-up was during the winter.
Myocardial infarction and reinfarction seem to be associated with high levels of PAI-1 activity,5 30 and spontaneous lysis of thrombi seems to be dependent on PAI-1 activity.31 Recent studies have shown a significant improvement in survival after myocardial infarction when treatment includes dietary intervention.32 33 A possible mechanism could be a positive effect of the dietary intervention on thrombogenesis through decreased coagulation (lowering of fibrinogen) and increased fibrinolysis (lowering of PAI-1 activity).
Exercise in general has a positive effect on health.34 The nonacute effect of exercise without energy restriction on PAI-1 and fibrinogen is not clear.29 35 36 37 The effect of addition of exercise to an energy-restrictive diet has never been reported. In our study of overweight postmenopausal women there was no additional effect of exercise on PAI-1 activity, PAI-1 Ag, TPA Ag, or fibrinogen. An explanation for the lack of effect of exercise may be the profound effect of the diet itself, which may leave no room for a relatively weaker exercise effect.
At the follow-up 6 months after the intervention, there were no
longer any convincing significant changes in PAI-1 activity, PAI-1 Ag,
TPA Ag, or fibrinogen. The women in the two intervention groups had
gained only about 2 kg and had thus maintained an 8-kg loss in body
weight. This could indicate that fibrinolysis is more
influenced by the energy-restrictive diet than by weight loss.
In summary, the balance between coagulation and fibrinolysis in overweight postmenopausal women tended to become less thrombogenic in the short term due to the diet with no additional effect of exercise.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Acknowledgments |
|---|
This study was supported by the Danish Medical Research Council, Copenhagen, Denmark (grant No. S 12-9528-2).
Received January 16, 1995; accepted November 13, 1995.
|
References |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
1. Bush TL, Fried LP, Barrett-Conner E. Cholesterol, lipoproteins and coronary heart disease in women. Clin Chem. 1988;34:B60-B70.
2. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J. 1987;114:413-419. [Medline] [Order article via Infotrieve]
3. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457-462. [Medline] [Order article via Infotrieve]
4.
Hamsten A. Hemostatic function and
coronary artery disease. N Engl J
Med. 1995;332:677-678.
5. Hamsten A, Defaire U, Walldius G, Dahlen G, Szamosi A, Landov C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9. [Medline] [Order article via Infotrieve]
6. Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607. [Abstract]
7. De Pergola G, De Mitrio V, Perricci A, Cignarelli M, Garruti G, Lomuscio S, Ferri G, Schiraldi O, Giorgino R. Influence of free testosterone on antigen levels of plasminogen activator inhibitor-1 in premenopausal women with central obesity. Metabolism. 1992;41:131-134. [Medline] [Order article via Infotrieve]
8. Kissebah AH, Peiris AN. Biology of regional body fat distribution: relationship to non-insulin-dependent diabetes mellitus. Diabetes Metab Rev. 1989;2:83-109.
9. Svendsen OL, Hassager C, Christiansen C. Relations and independence of body composition, sex hormones, fat distribution, and other cardiovascular risk factors in overweight postmenopausal women. Int J Obes. 1993;17:459-463.
10.
Ernst E. Does weight loss reduce plasma
fibrinogen? Br Heart J. 1993;70:116-118.
11.
Folsom AR, Qamhieh HK, Wing RR, Jeffery RW, Stinson VL,
Kuller LH, Wu KK. Impact of weight loss on
plasminogen activator inhibitor–1
(PAI-1), factor VII, and other hemostatic factors in moderately
overweight adults. Arterioscler Thromb. 1993;13:162-169.
12. Svendsen OL, Hassager C, Christiansen C. Effect of an energy-restrictive diet with or without exercise on lean tissue mass, resting metabolic rate, cardiovascular risk factors and bone in overweight postmenopausal women. Am J Med. 1993;95:131-140. [Medline] [Order article via Infotrieve]
13. Svendsen OL, Hassager C, Christiansen C. Six month's follow-up on exercise added to a short-term diet in overweight postmenopausal women: effects on body composition, resting metabolic rate, cardiovascular risk factors and bone. Int J Obes. 1994;18:692-698.
14. Hey H, Petersen T, Andersen T, Quaade F. Formula diet plus free additional food choice up to 1000 Kcal (4.2 MJ) compared with an isoenergetic conventional diet in the treatment of obesity: a randomized clinical trial. Clin Nutr. 1987;6:195-199.
15.
Mazess RB, Barden HS, Bidek JP, Hanson JA. Dual
energy x-ray absorptiometry for total-body and regional
bone-mineral and soft-tissue composition. Am J
Clin Nutr. 1990;51:1106-1112.
16.
Svendsen OL, Haarbo J, Hassager C, Christiansen
C. Accuracy of measurements of body composition by
dual-energy x-ray absorptiometry in vivo. Am J
Clin Nutr. 1993;57:605-608.
17. Svendsen OL, Hassager C, Bergmann I, Christiansen C. Measurement of abdominal and intraabdominal fat in postmenopausal women by dual energy x-ray absorptiometry and anthropometry: comparison with computed tomography. Int J Obes. 1993;17:45-51.
18. Dreager B, Wahlefeld AW, Ziegenhorn J. Eine Praktikable Methode zur HDL-Cholesterin-Bestimmung. Lab Med. 1982;18:198-202.
19. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem. 1972;18:499-502. [Abstract]
20. Andersen DC. Sex-hormone-binding globulin. Clin Endocrinol. 1974;3:69-96.[Medline] [Order article via Infotrieve]
21. Gough SCL, Rice PJS, McCormack L, Chapman C, Grant PJ. The relationship between plasminogen activator inhibitor 1 and insulin resistance in newly diagnosed type 2 diabetes mellitus. Diabet Med. 1993;10:638-642. [Medline] [Order article via Infotrieve]
22. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism. 1993;42:945-949. [Medline] [Order article via Infotrieve]
23. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism. 1990;39:1044-1048. [Medline] [Order article via Infotrieve]
24. De Pergola G, De Mitrio V, Cignarelli M, Garruti G, Giorgino G, Meola M, Giorgino R. Inverse relationship between cortisol excretion rate and plasminogen activator inhibitor-1 (PAI-1) antigen and activity in premenopausal obese women. Int J Obes. 1991;15:619-622. [Medline] [Order article via Infotrieve]
25. Larson B, Seidell J, Svärdsudd K, Welin L, Tibblin G, Wilhelmsen L, Björntorp P. Obesity, adipose tissue distribution and health in men: the study of men born in 1913. Appetite. 1989;13:37-44. [Medline] [Order article via Infotrieve]
26. Craveri A, Tornaghi G, Paganardi L, Ranieri R, Scaglioni S, Torchiana M, Giovannini M. Hemorheological changes in obesity. Clin Hemorheol. 1988;8:723-736.
27.
Haines AP, Imeson JD, Meade TW. Skinfold
thickness and cardiovascular risk factors.
Am J Epidemiol. 1987;126:86-94.
28. Kuyl JM, Slabber M, Barnard HC, Van Wyk HJ, Badenhorst AM. Observed changes in the plasma glucose, insulin, and C-peptide response after an oral glucose load, and plasma lipid and fibrinogen levels in morbidly obese females during a prolonged calorie-restricted diet. Clin Biochem. 1992;25:336-337. [Medline] [Order article via Infotrieve]
29. De Geus ECJ, Kluft C, De Bart ACW, Van Doornen JP. Effects of exercise training on plasminogen activator inhibitor activity. Med Sci Sports Exerc. 1992;24:1210-1219. [Medline] [Order article via Infotrieve]
30. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563. [Abstract]
31. Potter van Loon BJ, Rijken DC, Brommer EJ, Van der Maas APC. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost. 1992;67:101-105. [Medline] [Order article via Infotrieve]
32. De Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, Guidollet J, Toulboul P, Delaye J. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1994;343:1454-1459. [Medline] [Order article via Infotrieve]
33. Singh RB, Ratogi SS, Verma R, Laxmi B, Singh R, Ghosh S, Niaz MA. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ. 1992;302:1015-1019.
34.
Blair SN, Kohl HW, Paffenbarger RS, Clark DG, Cooper
KH, Gibbons LW. Physical fitness and all-cause mortality: a
prospective study of healthy men and women. JAMA. 1989;262:2395-2401.
35. Bourey EB, Santoro SA. Interactions of exercise, coagulation, platelets, and fibrinolysis: a brief review. Med Sci Sports Exerc. 1988;20:439-446. [Medline] [Order article via Infotrieve]
36. Gris JC, Schved JF, Feugeas O, Aguilar-Martinez P, Arnaud A, Sanchez N, Sarlat C. Impact of smoking, physical training and weight reduction on FVII, PAI-1 and hemostatic markers in sedentary men. Thromb Haemost. 1990;64:516-520. [Medline] [Order article via Infotrieve]
37.
Ernst E. Regular exercise reduces fibrinogen
levels: a review of longitudinal studies. Br J Sports
Med. 1993;27:175-176.
This article has been cited by other articles:
 |
|
 |
|
  B.-S. Youn, N. Kloting, J. Kratzsch, N. Lee, J. W. Park, E.-S. Song, K. Ruschke, A. Oberbach, M. Fasshauer, M. Stumvoll, et al. Serum Vaspin Concentrations in Human Obesity and Type 2 Diabetes Diabetes, February 1, 2008; 57(2): 372 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. F. Bodary Links Between Adipose Tissue and Thrombosis in the Mouse Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2284 - 2291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Christou, C. L. Gentile, C. A. DeSouza, D. R. Seals, and P. E. Gates Fatness Is a Better Predictor of Cardiovascular Disease Risk Factor Profile Than Aerobic Fitness in Healthy Men Circulation, April 19, 2005; 111(15): 1904 - 1914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rega, C. Kaun, T.W. Weiss, S. Demyanets, G. Zorn, S.P. Kastl, S. Steiner, D. Seidinger, C.W. Kopp, M. Frey, et al. Inflammatory Cytokines Interleukin-6 and Oncostatin M Induce Plasminogen Activator Inhibitor-1 in Human Adipose Tissue Circulation, April 19, 2005; 111(15): 1938 - 1945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Anand, Q. Yi, H. Gerstein, E. Lonn, R. Jacobs, V. Vuksan, K. Teo, B. Davis, P. Montague, and S. Yusuf Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease Circulation, July 29, 2003; 108(4): 420 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Muller, F. W. G. Leebeek, J. A. M. J. L. Janssen, S. W. J. Lamberts, L. Hofland, and A. J. van der Lely Acute Effect of Pegvisomant on Cardiovascular Risk Markers in Healthy Men: Implications for the Pathogenesis of Atherosclerosis in GH Deficiency J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5165 - 5171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Kohler and P. J. Grant Plasminogen-Activator Inhibitor Type 1 and Coronary Artery Disease N. Engl. J. Med., June 15, 2000; 342(24): 1792 - 1801. [Full Text] [PDF]
|
|
|
|
|
|
A. Mavri, M. Stegnar, M. Krebs, J. T. Sentocnik, M. Geiger, and B. R. Binder Impact of Adipose Tissue on Plasma Plasminogen Activator Inhibitor-1 in Dieting Obese Women Arterioscler Thromb Vasc Biol, June 1, 1999; 19(6): 1582 - 1587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. LaRosa Triglycerides and Coronary Risk in Women and the Elderly Arch Intern Med, May 12, 1997; 157(9): 961 - 968. [Abstract] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||